vs
精工集团（CRDO）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
精工集团的季度营收约是REPLIGEN CORP的1.4倍（$268.0M vs $197.9M），精工集团净利率更高（30.8% vs 6.7%，领先24.1%），精工集团同比增速更快（272.1% vs 13.6%），精工集团自由现金流更多（$38.5M vs $17.6M），过去两年精工集团的营收复合增速更高（124.8% vs 14.4%）
精工集团是由精工集团株式会社及其子公司、关联企业组成的企业集团。该集团原由精工控股株式会社、精工仪器株式会社和精工爱普生株式会社三家核心企业构成，三家企业均以钟表技术为核心联结。目前爱普生仍为精工集团开发生产腕表，但爱普生及其子公司已不属于精工集团旗下成员。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
CRDO vs RGEN — 直观对比
营收规模更大
CRDO
是对方的1.4倍
$197.9M
营收增速更快
CRDO
高出258.4%
13.6%
净利率更高
CRDO
高出24.1%
6.7%
自由现金流更多
CRDO
多$20.9M
$17.6M
两年增速更快
CRDO
近两年复合增速
14.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $268.0M | $197.9M |
| 净利润 | $82.6M | $13.3M |
| 毛利率 | 67.5% | 52.5% |
| 营业利润率 | 29.4% | 9.0% |
| 净利率 | 30.8% | 6.7% |
| 营收同比 | 272.1% | 13.6% |
| 净利润同比 | 2055.9% | 143.9% |
| 每股收益（稀释后） | $0.44 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRDORGEN
| Q4 25 | $268.0M | $197.9M | ||
| Q3 25 | $223.1M | $188.8M | ||
| Q2 25 | $170.0M | $182.4M | ||
| Q1 25 | $135.0M | $169.2M | ||
| Q4 24 | $72.0M | $174.1M | ||
| Q3 24 | $59.7M | $154.9M | ||
| Q2 24 | $60.8M | $154.1M | ||
| Q1 24 | $53.1M | $151.3M |
净利润CRDORGEN
| Q4 25 | $82.6M | $13.3M | ||
| Q3 25 | $63.4M | $14.9M | ||
| Q2 25 | $36.6M | $14.9M | ||
| Q1 25 | $29.4M | $5.8M | ||
| Q4 24 | $-4.2M | $-30.3M | ||
| Q3 24 | $-9.5M | $-654.0K | ||
| Q2 24 | $-10.5M | $3.3M | ||
| Q1 24 | $428.0K | $2.1M |
毛利率CRDORGEN
| Q4 25 | 67.5% | 52.5% | ||
| Q3 25 | 67.4% | 53.2% | ||
| Q2 25 | 67.2% | 50.0% | ||
| Q1 25 | 63.6% | 53.6% | ||
| Q4 24 | 63.2% | 26.1% | ||
| Q3 24 | 62.4% | 50.0% | ||
| Q2 24 | 65.8% | 49.8% | ||
| Q1 24 | 61.4% | 49.5% |
营业利润率CRDORGEN
| Q4 25 | 29.4% | 9.0% | ||
| Q3 25 | 27.2% | 8.9% | ||
| Q2 25 | 19.9% | 7.6% | ||
| Q1 25 | 19.4% | 3.9% | ||
| Q4 24 | -11.7% | -17.7% | ||
| Q3 24 | -24.2% | -5.1% | ||
| Q2 24 | -13.0% | 1.0% | ||
| Q1 24 | -11.1% | 1.3% |
净利率CRDORGEN
| Q4 25 | 30.8% | 6.7% | ||
| Q3 25 | 28.4% | 7.9% | ||
| Q2 25 | 21.5% | 8.2% | ||
| Q1 25 | 21.7% | 3.4% | ||
| Q4 24 | -5.9% | -17.4% | ||
| Q3 24 | -16.0% | -0.4% | ||
| Q2 24 | -17.2% | 2.2% | ||
| Q1 24 | 0.8% | 1.4% |
每股收益（稀释后）CRDORGEN
| Q4 25 | $0.44 | $0.24 | ||
| Q3 25 | $0.34 | $0.26 | ||
| Q2 25 | $0.22 | $0.26 | ||
| Q1 25 | $0.16 | $0.10 | ||
| Q4 24 | $-0.03 | $-0.55 | ||
| Q3 24 | $-0.06 | $-0.01 | ||
| Q2 24 | $-0.06 | $0.06 | ||
| Q1 24 | $0.00 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $813.6M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $1.3B | $2.1B |
| 总资产 | $1.4B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资CRDORGEN
| Q4 25 | $813.6M | $767.6M | ||
| Q3 25 | $479.6M | $748.7M | ||
| Q2 25 | $431.3M | $708.9M | ||
| Q1 25 | $379.2M | $697.2M | ||
| Q4 24 | $383.0M | $757.4M | ||
| Q3 24 | $398.6M | $784.0M | ||
| Q2 24 | $410.0M | $809.1M | ||
| Q1 24 | $409.1M | $780.6M |
总债务CRDORGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CRDORGEN
| Q4 25 | $1.3B | $2.1B | ||
| Q3 25 | $781.4M | $2.1B | ||
| Q2 25 | $681.6M | $2.1B | ||
| Q1 25 | $618.2M | $2.0B | ||
| Q4 24 | $567.9M | $2.0B | ||
| Q3 24 | $553.1M | $2.0B | ||
| Q2 24 | $540.2M | $2.0B | ||
| Q1 24 | $534.0M | $2.0B |
总资产CRDORGEN
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | $905.2M | $2.9B | ||
| Q2 25 | $809.3M | $2.9B | ||
| Q1 25 | $719.9M | $2.9B | ||
| Q4 24 | $638.6M | $2.8B | ||
| Q3 24 | $644.9M | $2.8B | ||
| Q2 24 | $601.9M | $2.9B | ||
| Q1 24 | $592.5M | $2.8B |
负债/权益比CRDORGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $61.7M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $38.5M | $17.6M |
| 自由现金流率自由现金流/营收 | 14.4% | 8.9% |
| 资本支出强度资本支出/营收 | 8.7% | 4.1% |
| 现金转化率经营现金流/净利润 | 0.75× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $143.6M | $93.9M |
8季度趋势，按日历期对齐
经营现金流CRDORGEN
| Q4 25 | $61.7M | $25.7M | ||
| Q3 25 | $54.2M | $48.1M | ||
| Q2 25 | $57.8M | $28.6M | ||
| Q1 25 | $4.2M | $15.0M | ||
| Q4 24 | $10.3M | $39.2M | ||
| Q3 24 | $-7.2M | $49.3M | ||
| Q2 24 | $4.2M | $42.2M | ||
| Q1 24 | $-1.0M | $44.7M |
自由现金流CRDORGEN
| Q4 25 | $38.5M | $17.6M | ||
| Q3 25 | $51.3M | $43.4M | ||
| Q2 25 | $54.2M | $21.5M | ||
| Q1 25 | $-383.0K | $11.4M | ||
| Q4 24 | $-11.7M | $33.6M | ||
| Q3 24 | $-13.1M | $42.3M | ||
| Q2 24 | $962.0K | $37.4M | ||
| Q1 24 | $-6.1M | $36.4M |
自由现金流率CRDORGEN
| Q4 25 | 14.4% | 8.9% | ||
| Q3 25 | 23.0% | 23.0% | ||
| Q2 25 | 31.9% | 11.8% | ||
| Q1 25 | -0.3% | 6.8% | ||
| Q4 24 | -16.2% | 19.3% | ||
| Q3 24 | -21.9% | 27.3% | ||
| Q2 24 | 1.6% | 24.3% | ||
| Q1 24 | -11.6% | 24.0% |
资本支出强度CRDORGEN
| Q4 25 | 8.7% | 4.1% | ||
| Q3 25 | 1.3% | 2.5% | ||
| Q2 25 | 2.1% | 3.9% | ||
| Q1 25 | 3.4% | 2.1% | ||
| Q4 24 | 30.5% | 3.2% | ||
| Q3 24 | 9.8% | 4.5% | ||
| Q2 24 | 5.3% | 3.1% | ||
| Q1 24 | 9.6% | 5.5% |
现金转化率CRDORGEN
| Q4 25 | 0.75× | 1.93× | ||
| Q3 25 | 0.85× | 3.23× | ||
| Q2 25 | 1.58× | 1.92× | ||
| Q1 25 | 0.14× | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | -2.42× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRDO
| Other | $132.1M | 49% |
| HK | $104.4M | 39% |
| RESTOFTHEWORLD | $31.5M | 12% |
RGEN
暂无分部数据
